591 related articles for article (PubMed ID: 22038336)
1. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction.
Paoletti E; Ratto E; Bellino D; Marsano L; Cassottana P; Cannella G
J Nephrol; 2012; 25(5):709-18. PubMed ID: 22038336
[TBL] [Abstract][Full Text] [Related]
2. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
3. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
Burkhalter F; Oettl T; Descoeudres B; Bachmann A; Guerke L; Mihatsch MJ; Dickenmann M; Steiger J
Transplant Proc; 2012 Dec; 44(10):2961-5. PubMed ID: 23195006
[TBL] [Abstract][Full Text] [Related]
4. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
5. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
6. Can we eliminate both calcineurin inhibitors and steroids?
Lebranchu Y
Transplant Proc; 2010 Nov; 42(9 Suppl):S25-8. PubMed ID: 21095446
[TBL] [Abstract][Full Text] [Related]
7. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
[TBL] [Abstract][Full Text] [Related]
8. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
Luna E; Cerezo I; Macias R; Villa J; Martinez C; Cubero J; Martinez R; Ferreira F; García C
Transplant Proc; 2011; 43(6):2187-90. PubMed ID: 21839229
[TBL] [Abstract][Full Text] [Related]
9. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial.
Paoletti E; Amidone M; Cassottana P; Gherzi M; Marsano L; Cannella G
Am J Kidney Dis; 2008 Aug; 52(2):324-30. PubMed ID: 18585837
[TBL] [Abstract][Full Text] [Related]
10. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial.
Weir MR; Pearson TC; Patel A; Peddi VR; Kalil R; Scandling J; Chan L; Baliga P; Melton L; Mulgaonkar S; Waid T; Schaefer H; Youssef N; Anandagoda L; McCollum D; Lawson S; Gordon R
Transplantation; 2017 Jan; 101(1):157-165. PubMed ID: 26950714
[TBL] [Abstract][Full Text] [Related]
11. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity.
Höcker B; Feneberg R; Köpf S; Weber LT; Waldherr R; Wühl E; Tönshoff B
Pediatr Transplant; 2006 Aug; 10(5):593-601. PubMed ID: 16856996
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial.
Weir MR; Mulgaonkar S; Chan L; Shidban H; Waid TH; Preston D; Kalil RN; Pearson TC
Kidney Int; 2011 Apr; 79(8):897-907. PubMed ID: 21191361
[TBL] [Abstract][Full Text] [Related]
13. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
Herlenius G; Felldin M; Nordén G; Olausson M; Bäckman L; Gustafsson B; Friman S
Transplant Proc; 2010 Dec; 42(10):4441-8. PubMed ID: 21168715
[TBL] [Abstract][Full Text] [Related]
14. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Chhabra D; Skaro AI; Leventhal JR; Dalal P; Shah G; Wang E; Gallon L
Clin J Am Soc Nephrol; 2012 Mar; 7(3):504-12. PubMed ID: 22282478
[TBL] [Abstract][Full Text] [Related]
15. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial.
Teperman L; Moonka D; Sebastian A; Sher L; Marotta P; Marsh C; Koneru B; Goss J; Preston D; Roberts JP;
Liver Transpl; 2013 Jul; 19(7):675-89. PubMed ID: 23775875
[TBL] [Abstract][Full Text] [Related]
16. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
[TBL] [Abstract][Full Text] [Related]
17. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
Pliszczynski J; Kahan BD
Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
[TBL] [Abstract][Full Text] [Related]
18. Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011.
Ignjatović L; Hrvacević R; Jovanović D; Kovacević Z; Vavić N; Rabrenović V; Tomić A; Aleksić P; Drasković-Pavlović B; Dujić A; Karan Z; Maksić D
Vojnosanit Pregl; 2013 Sep; 70(9):848-53. PubMed ID: 24266313
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors.
Yu JH; Kim KW; Kim BM; Chung BH; Cho ML; Choi BS; Park CW; Kim YS; Yang CW
Korean J Intern Med; 2016 May; 31(3):552-9. PubMed ID: 26968190
[TBL] [Abstract][Full Text] [Related]
20. De novo cancer avoidance after renal transplantation: A case-control study on low-dose sirolimus combined with a calcineurin inhibitor.
Chen KH; Lee CY; Wu FL; Yang CY; Yeh CC; Hu RH; Tsai MK
J Formos Med Assoc; 2015 Jun; 114(6):526-31. PubMed ID: 25843527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
